Amgen Inc. fell $2.32 or 2.3 percent, to $99.18. Biogen Idec fell $7.00 or 3.3 percent, to $203.80. Celgene Corp. fell $3.35 or 2.8 percent, to $116.89.
Amgen Inc. fell$. 65 or. 6 percent, to $100.85. Biogen Idec fell $3.70 or 1.8 percent, to $207.10. Celgene Corp. fell $1.57 or 1.3 percent, to $118.67.
Amgen Inc. rose$. 04 or percent, to $101.54. Biogen Idec fell$. 98 or. 5 percent, to $209.82. Celgene Corp. fell$. 84 or. 7 percent, to $119.40.
Amgen Inc. rose $2.42 or 2.4 percent, to $101.50. Biogen Idec rose $3.05 or 1.5 percent, to $210.80. Celgene Corp. rose $2.54 or 2.2 percent, to $120.24.
Amgen Inc. rose $2.04 or 2.1 percent, to $101.12. Biogen Idec rose $2.66 or 1.3 percent, to $210.41. Celgene Corp. rose $2.28 or 1.9 percent, to $119.98.
Amgen Inc. rose$. 74 or. 7 percent, to $99.82. Biogen Idec rose$. 68 or. 3 percent, to $208.43. Celgene Corp. rose$. 37 or. 3 percent, to $118.07.
Amgen Inc. rose $1.66 or 1.7 percent, to $99.08. Biogen Idec fell $4.24 or 2.0 percent, to $207.75. Celgene Corp. fell $1.66 or 1.4 percent, to $117.70.
Amgen Inc. rose $2.16 or 2.2 percent, to $99.58. Biogen Idec fell $2.31 or 1.1 percent, to $209.68. Celgene Corp. fell$. 97 or. 8 percent, to $118.40.
Amgen Inc. rose $2.14 or 2.2 percent, to $99.56. Biogen Idec rose $1.78 or. 8 percent, to $213.77. Celgene Corp. rose$. 58 or. 5 percent, to $119.94.
Amgen Inc. fell $1.09 or 1.1 percent, to $97.42. Biogen Idec rose $2.41 or 1.1 percent, to $211.99. Celgene Corp. fell$. 90 or. 7 percent, to $119.36.
Amgen Inc. fell $1.05 or 1.1 percent, to $97.46. Biogen Idec rose $2.35 or 1.1 percent, to $211.93. Celgene Corp. fell$. 73 or. 6 percent, to $119.53.
Amgen Inc. fell$. 67 or. 7 percent, to $97.84. Biogen Idec rose$. 74 or. 4 percent, to $210.32. Celgene Corp. fell$. 71 or. 6 percent, to $119.55.
Biotech drugmaker Amgen Inc. said Thursday that the Food and Drug Administration has approved a new use for its bone drug Xgeva. The company, based in Thousand Oaks, Calif., said it now can market Xgeva for treating a rare condition, giant cell tumor of bone, when surgery isn't practical.
Amgen Inc. rose $2.14 or 2.2 percent, to $98.51. Biogen Idec rose $3.03 or 1.5 percent, to $209.58. Celgene Corp. rose $2.15 or 1.8 percent, to $120.26.
Amgen Inc. rose $1.41 or 1.5 percent, to $97.78. Biogen Idec rose $3.06 or 1.5 percent, to $209.61. Celgene Corp. rose $1.88 or 1.6 percent, to $119.99.
Amgen Inc. rose$. 50 or. 5 percent, to $96.87. Biogen Idec rose $1.23 or. 6 percent, to $207.78. Celgene Corp. rose$. 38 or. 3 percent, to $118.49.
Amgen Inc. fell $1.56 or 1.6 percent, to $96.37. Biogen Idec fell $16.48 or 7.4 percent, to $206.55. Celgene Corp. fell$. 64 or. 5 percent, to $118.11.
Amgen Inc. fell $1.27 or 1.3 percent, to $96.66. Biogen Idec fell $15.68 or 7.0 percent, to $207.35. Celgene Corp. rose$. 57 or. 5 percent, to $119.32.
THOUSAND OAKS, Calif.-- Biotech drugmaker Amgen Inc. reported Wednesday that its experimental drug for ovarian cancer helped patients live 1.8 months longer without their disease spreading, compared with patients getting placebo. Amgen is studying its drug trebananib in combination with paclitaxel to treat recurring ovarian cancer.
NEW YORK-- Cytokinetics Inc. and Amgen Inc. said Wednesday that they are expanding their collaboration on a drug to treat heart failure in a deal worth at least $25 million. Cytokinetics said Amgen will make an upfront payment of $15 million and has agreed to buy $10 million in Cytokinetics stock, or 8.4 million shares for $1.19 per share.
DuckDuckGo CEO Gabriel Weinberg says web traffic on his search engine, billed as an alternative to Google that doesn't store your private information, surged 33 percent after the NSA news broke. Weinberg discusses the model of his search engine, and how the company makes money.
Wednesday, 19 Jun 2013 | 6:31 AM ETJohn Silvia, Wells Fargo Securities, and Barbara Marcin, Gabelli Dividend Income Fund, discuss whether investors should reconsider allocating their portfolios as the Fed wraps up its two-day policy meeting.
Wednesday, 19 Jun 2013 | 8:53 AM ETKen Langone, Invemed Associates chairman and president, called Fed Chairman Ben Bernanke a "lame duck."